
Aravive ARAV
Quarterly report 2023-Q3
added 11-09-2023
Aravive Total Current Liabilities 2011-2026 | ARAV
Annual Total Current Liabilities Aravive
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 22.1 M | 17.9 M | 9.46 M | 4.97 M | 1.94 M | 5.59 M | - | 8.83 M | 6.92 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 22.1 M | 1.94 M | 9.72 M |
Total Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acorda Therapeutics
ACOR
|
228 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
1.93 M | - | 4.01 % | $ 150 M | ||
|
ARCA biopharma
ABIO
|
13 M | - | 1052.0 % | $ 415 M | ||
|
Albireo Pharma
ALBO
|
45.3 M | - | -0.23 % | $ 916 M | ||
|
Adagene
ADAG
|
38.2 M | $ 2.83 | -2.75 % | $ 159 M | ||
|
Biogen
BIIB
|
5.53 B | $ 177.27 | 0.62 % | $ 25.8 B | ||
|
ANI Pharmaceuticals
ANIP
|
194 M | $ 81.19 | -0.98 % | $ 1.57 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | ||
|
Amgen
AMGN
|
23.1 B | $ 339.82 | -0.91 % | $ 182 B | ||
|
Aeglea BioTherapeutics
AGLE
|
54.1 M | - | - | $ 1.01 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | ||
|
Aytu BioScience
AYTU
|
63.1 M | $ 2.56 | -0.78 % | $ 16.1 M | ||
|
Akero Therapeutics
AKRO
|
39.8 M | - | - | $ 3.67 B | ||
|
CASI Pharmaceuticals
CASI
|
13.2 M | $ 0.99 | - | $ 135 M | ||
|
Catalyst Biosciences
CBIO
|
20 M | $ 10.0 | -1.43 % | $ 658 M | ||
|
Allena Pharmaceuticals
ALNA
|
15.7 M | - | 3.16 % | $ 1.9 M | ||
|
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M | ||
|
Cerus Corporation
CERS
|
63.6 M | $ 2.3 | -1.08 % | $ 424 M | ||
|
Aptose Biosciences
APTO
|
4.46 M | - | -45.71 % | $ 1.2 M | ||
|
Brickell Biotech
BBI
|
1.66 M | - | -5.38 % | $ 6.06 M | ||
|
Applied Molecular Transport
AMTI
|
15.1 M | - | - | $ 10.1 M | ||
|
Beam Therapeutics
BEAM
|
182 M | $ 28.26 | -3.52 % | $ 2.33 B | ||
|
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - | ||
|
Athira Pharma
ATHA
|
13.1 M | - | - | $ 269 M | ||
|
Atreca
BCEL
|
16.3 M | - | -11.76 % | $ 5.79 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
195 M | $ 68.89 | -0.33 % | $ 9.21 B | ||
|
Catalyst Pharmaceuticals
CPRX
|
121 M | $ 24.53 | -0.2 % | $ 2.91 B | ||
|
Cardiff Oncology
CRDF
|
13.4 M | $ 1.68 | 3.75 % | $ 80.1 M | ||
|
AgeX Therapeutics
AGE
|
5.91 M | - | -10.17 % | $ 12.2 K | ||
|
Akouos
AKUS
|
16.8 M | - | 0.23 % | $ 488 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
3.77 M | - | -9.72 % | $ 5.89 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
72.8 M | - | -15.15 % | $ 60.3 M | ||
|
Berkeley Lights
BLI
|
45.5 M | - | -7.31 % | $ 87 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
2.05 M | $ 4.03 | -1.71 % | $ 8.77 B | ||
|
Amneal Pharmaceuticals
AMRX
|
1.13 B | $ 13.77 | -2.45 % | $ 4.25 B | ||
|
AIkido Pharma
AIKI
|
3.78 M | - | 1.93 % | $ 17.4 M | ||
|
Bellerophon Therapeutics
BLPH
|
5.4 M | - | -74.18 % | $ 955 K | ||
|
Acer Therapeutics
ACER
|
19 M | - | 2.71 % | $ 14 M | ||
|
Alpine Immune Sciences
ALPN
|
58 M | - | - | $ 2.17 B |